

PEDIATRIC PHARMACOTHERAPY

A Monthly Newsletter for Health Care Professionals from the
Children's Medical Center at the University of Virginia

Volume 9 Number 1

January 2003

Eight-year Cumulative Index

(key term followed by volume/issue and type of citation:

M= main feature; L= literature review; F= FDA update; C= correction)

A			
Acellular pertussis vaccine	3/2 L, 3/7 M, 3/9 L	Asthma, magnesium in	5/7 L
Acetaminophen	2/7 M	Asthma, single isomer therapy	6/1 L
Acetaminophen, overdose	6/3 M	Asthma, steroids	1/1 L
Acetaminophen, rectal	5/12 L, 7/9 M	Asthma, therapy in teens	1/8 L
Acetaminophen, renal effects	1/6 L	Atenolol, use in Marfan syndrome	1/5 L
Acetaminophen, TEN with	6/3 L	Atomoxetine	8/1 M, 8/4 M
Aclometasone	2/1 M	Atomoxetine/Paroxetine	8/12 L
Acyclovir	8/6 M	Atorvastatin	8/9 M
Adverse reactions, causality	2/11 L	Atropine	2/12 M
Adverse reactions, frequency	2/10 L, 4/11 L	Attention-deficit/hyperactivity disorder (ADHD), therapy	1/12 M, 4/10 L, 8/1 L, 8/2 M, 8/3 M, 8/4 M
Adverse reactions, reporting	1/3 M	Atypical antipsychotics	7/8 M
Albuterol	2/5 M, 8/1 L	Autism, therapy	1/2 L
Alprostadil (PGE ₁)	6/9 M	Azithromycin	2/2 M, 4/9 L, 8/1 L
Alteplase	5/8 M	Azithromycin, kinetics	3/11 L
Alteplase, use in ECMO	5/6 L	B	
Alternative therapies	4/5 M	Bayesian kinetics	3/2 L
Amincinonide	2/1 M	Beclomethasone	7/5 M
Amiloride, kinetics	3/5 L	Benzalkonium chloride	2/9 M
Aminoglycosides, in transplant	3/11 L	Benzyl alcohol	2/9 M
Amiodarone	7/12 M	Betamethasone	2/1 M
Amoxicillin, adverse effects	5/3 L	Betamethasone, adverse effects	3/11 L
Ampicillin, oral in neonates	4/1 L	Black box warnings	8/12 M
Ampicillin-clavulanate	8/1 L	Bone marrow trans., gentamicin	3/11 L
Analgesics, dosing	4/2 L	Bone marrow trans., tobramycin	3/11 L
Anesthetics, adverse effects	4/11 L	Breastfeeding, drugs given during	1/12 L
Angiotensin converting enzyme (ACE) inhibitors	2/2 L	Breastfeeding, effect on liver	2/2 M
Antiarrhythmics, pregnancy	5/5 L	Brompheniramine	1/9 M
Antibiotics, allergies	1/12 L	Budesonide	4/10 L, 7/3 L, 7/5 M, 7/9 C, 8/1 M
Antibiotics, comparison of oral	2/4 L	Bumetanide	1/10 M
Antibiotics, nephropathy from	5/7 L	Buprenorphine, withdrawal	4/2 L
Antibiotics, selection	4/7 L	Bupropion	8/4 M
Antibiotics, use in infants	5/11 L	Buspirone	8/1 L, 8/4 M
Anticonvulsants, kinetics	1/12 L, 2/1 L	C	
Anticonvulsants, review	2/11 L, 6/10 L, 8/6 L	Caffeine	1/3 L, 5/12 M
Anticonvulsants, withdrawal	4/4 L	Caffeine, kinetics	3/8 L, 7/7 L
Antiemetic guidelines	5/6 L, 6/11 L	Calcium chloride	2/12 M
Antifungals, review	3/4 L	Carbamazepine	2/11 M
Antihistamines	1/9 M, 7/3 L, 7/4 M	Carbamazepine/Cyclosporine	1/6 L
Antineoplastics, endocrine effect	3/2 L	Carbamazepine, drug interact.	2/10 L
Antipyretics	2/7 M	Carbamazepine/Grapefruit juice	4/11 L
Antipyretics, kinetics/dynamics	5/8 L	Carbamazepine, hepatorenal failure	5/7 L
Ardeparin	3/6 M	Cardiovascular drugs, kinetics	1/1 L
Arrhythmias, drug-induced	3/11 L	Catheters, saline vs. heparin	4/4 L
Astemizole	1/9 M		

Cefaclor	2/6 M	Digoxin, drug interactions	1/4 L
Cefadroxil	2/6 M	Dilution of medications	1/8 L
Cefepime	1/8 L, 3/2 L, 5/5 M	Diphenhydramine	1/9 M
Cefixime	2/6 M	Diuretics	1/10 M
Cefpodoxime	2/6 M	Dornase alpha	1/1 L, 2/3 L
Cefprozil	2/6 M	Dornase alpha, cost analysis	1/6 L
Ceftazidime	1/4 L	Doxapram	8/1 M, 8/2 L
Ceftazidime, use in infants	2/2 L	Doxepin, breastfeeding with	5/9 L
Ceftibuten	2/6 M, 3/11 L	Doxepin, toxicity with topical use	6/7 L
Ceftriaxone	3/2 M, 8/7 L	d-penicillamine, dosing	6/7 L
Cefuroxime axetil	2/6 M, 2/7 L	Droperidol	8/1 M
Cefuroxime, during pregnancy	6/4 L	Drug administration in ventilators	5/5 L
Celecoxib	8/12 L	Drug approval process, FDA	1/11 M
Cephalexin	2/6 M	Drug expenditures	4/3 L
Cephalosporins, review of oral	2/6 M	Drug information	8/9 L, 8/12 M
Cephradine	2/6 M	Drug interactions, renal	4/7 L
Cetirizine	3/4 L, 7/4 M	Drug labeling, pediatrics	3/9 F
Chlorothiazide	1/10 M	Drug-nutrient interactions	1/5 M
Chlorpheniramine	1/9 M	Drug reactions, idiosyncratic	2/10 L
Ciprofloxacin	4/12 M	Dyes and colorants	2/9 M
Cisapride, drug interactions	2/11 M	E	
Clarithromycin	2/2 M	Eicosanoid research	4/9 L
Clarithromycin/Itraconazole	5/12 L	EMLA, subcutaneous injections	2/1 M
Clarithromycin, kinetics	6/1 L	EMLA, use for lumbar puncture	3/11 L
Clemastine	1/9 M	Enalapril	8/10 L
Clobetasol	2/1 M	Enoxaparin	3/6 M, 7/2 L
Clocortolone	2/1 M	Enteral feedings/Phenytoin	6/9 L
Clonazepam, kinetics	2/3 L	Epilepsy, treatment	2/4 L
Clonidine	1/12 M	Epinephrine	2/12 M
Clonidine, use in ADHD	6/2 L, 8/4 M	Epoetin	1/3 L, 5/12 M
Clostridium difficile	6/6 M	Epoetin, enteral administration	6/7 L, 8/11 M
Clozapine	7/8 M	Erythema multiforme	6/11 L
Combination vaccines	3/7 M	Erythromycin	4/11 M
Compliance	1/4 L, 3/8 M, 5/11 L, 7/2 L, 8/1 L	Erythromycin	2/2 M
Compliance, effect of taste	3/11 L	Erythropoietin kinetics	5/2 L
Conscious sedation	2/3 L	Erythromycin/Sertraline	5/9 L
Corticosteroids, intranasal	7/5 M	Ethanol	2/9 M
Corticosteroids, topical	2/1 M	Etoposide, kinetics/dynamics	1/9 L
Co-trimoxazole	4/4 M	Excipients, pharmaceutical	2/9 M
Creatinine clearance, prediction	1/10 L	Extravasations, IV	4/1 M
Cromolyn	5/7 M	F	
Crotamiton	1/8 M	Famotidine	2/9 L, 4/2 M
Croup, management	3/5 L	Famotidine, kinetics/dynamics	2/3 L
Cyclic antidepressant toxicity	1/5 L	Felbamate, review	5/11 L
Cyclosporine	1/4 M	Fexofenadine	7/4 M
Cyclosporine, absorption of	2/3 L	Flavorings	2/9 M
Cyclosporine/Carbamazepine	1/6 L	Fluconazole	3/12 M
Cyclosporine, drug interactions	2/4 L	Fluconazole, kinetics	1/2 L
Cyclosporine, dynamics	5/10 L	Fluconazole/Warfarin	2/5 L
Cyclosporine, kinetics	3/7 L	Flunisolide	7/5 M
Cyclosporine/Norfloxacin	1/11 L	Fluocinolone	2/1 M
Cystic fibrosis, drug metabolism	1/1 L	Fluocinonide	2/1 M
Cystic fibrosis, ibuprofen in	5/5 L	Fluoxetine	2/10 M, 8/4 M
Cystic fibrosis, kinetics	5/2 L	Flurandrenolide	2/1 M
Cystic fibrosis, therapy	1/11 L	Fluticasone	2/1 M, 7/5 M
Cystic fibrosis, tobramycin in	2/5 L	Fluvastatin	8/9 M
Cytochrome P450 enzymes	1/7 L, 3/5 M, 4/3 L, 6/2 L	Fluvoxamine	2/10 M
D		Food and Drug Administration (FDA)	1/11 M, 6/12 M, 8/1 M
Dalteparin	3/6 M	Furosemide	1/10 M
Darbepoetin	8/1 M	Furosemide, bolus vs. intermittent	4/3 L
Depression, treatment of	5/2 L	G	
Desensitization, antimicrobials	3/11 L	Gabapentin	4/6 L, 7/6 L, 8/10 M
Desonide	2/1 M	Gabapentin, stability in food	4/5 L
Desoximetasone	2/1 M	G-CSF	1/1L
Dexamethasone	2/1 M	G-CSF, binding to catheters	1/2 L
Dexamethylphenidate	8/1M	G-CSF, enteral administration	6/11 L
Dextroamphetamine	1/12 M, 8/1 M, 8/3 M	Gentamicin	4/1 L, 8/1 L
Diflorasone	2/1 M	Gentamicin, neonatal dosing	1/7 L, 7/2 L
		Gentamicin, use in leukemics	2/1 L
		Gestational diabetes, therapy	2/7 L
		Gloves, permeability	5/12 L

Granisetron	3/9 M	Measles vaccine, review	5/2 L, 7/3 M
Grapefruit juice/Carbamazepine	4/11 L	Medication errors, prevention	1/1 L, 5/10 M
Group B Strep. ,therapy	3/8 L	Medication taste, compliance	3/11 L
Growth hormone	3/7 L	MedWatch	1/3 M
H		MedWatch, data from	1/8 L
Halbetasol	2/1 M	Menstrual cycle, metabolism	4/6 L
Halcinonide	2/1 M	Meropenem	3/10 L
Half-life	1/7 M		4/7 M
Halving methylphenidate	3/11 L	Metered-dose inhalers, changes	4/3 L
Halving tablets	4/3 L	Metformin	7/2 L
Heparin, dynamics	3/5 L	Methadone	6/7 M, 8/1 L
Heparin vs. saline in catheters	4/4 L	Methemoglobinemia	2/8 L
Herbal medicines	3/11 L, 4/5 M	Methotrexate, kinetics	1/4 L
	6/4 L	Methylphenidate	1/12 M
HIV, therapy in children	1/6 L		3/10 L, 8/2 M
HMG-CoA reductase inhibitors	5/12 L, 8/9 M	Methylphenidate, halving tabs	3/11 L
Hydrochlorothiazide	1/10 M	Methylphenidate, kinetics	5/10 L, 6/2 L
Hydrocortisone	2/1 M	Methylphenidate, tolerance	6/1 L
Hydroxyurea, use in pregnancy	6/1 L	Metoclopramide	1/3 L
Hypercholesterolemia	3/6 L, 8/9 M	Metoclopramide, kinetics	4/5 L
Hypertension, treatment	1/1 L, 6/5 L	Metolazone	1/10 M
I		Midazolam	4/9 L, 6/1 M,
Ibuprofen	2/7 M		7/6 L, 8/1 L
Ibuprofen, overdose	1/10 L, 4/9 L	Midazolam, clearance	2/2 L
Ibuprofen, pyloric stricture	5/9 L	Midazolam, compatibility	1/12 L
Ibuprofen, renal toxicity	6/4 M	Midazolam, intranasal	2/5 L
Ibuprofen, use in cystic fibrosis	5/5 L	Midazolam, use in neonates	1/2 L
Idiosyncratic drug reactions	2/10 L	Milk:Plasma ratio	2/4 M
Ifosfamide, metabolites	4/6 L	Mineral supplements	3/2 M
Imipenem-cilastatin	2/2 L	Minocycline-induced lupus	3/11 L
Immune globulin, use in HIV	1/5 L	Mirtazapine	6/2 M
Indinavir, nephrotoxicity	3/11 L	Modernization Act, FDA	6/12 M
Infliximab	5/11 M, 7/9 L,	Mometasone	2/1 M, 5/12 M,
	8/1 M		7/5 M
INR	1/1 M	Montelukast	4/10 M, 7/9 L
Internet, as information source	5/6 M, 5/12 L	Moricizine	1/12 L
Intranasal steroids	7/5 M	Morphine, use in neonates	1/1 L
Isoniazid	1/2 L	Muromonab-CD3, anaphylaxis	6/2 L
Isoniazid, kinetics	3/11 L	Mycophenolate	4/1 L, 4/8 M
Isotretinoin	7/7 M, 8/1 M	N	
Isradipine	3/7 L, 8/8 L	Nalmefene, dosing/kinetics	6/9 L
Itraconazole/Clarithromycin	5/12 L	Naloxone	2/12 M, 8/8 M
IV extravasations	4/1 M	Naratriptan	7/5 L
J		Nebulizer solutions, preservative	4/3 L
Juvenile rheumatoid arthritis (JRA), therapy	5/12 L	Nedocromil	5/7 M
K		New drug development	1/7 L
Kawasaki syndrome, therapy	5/12 L	Nitric oxide	7/4 L
Kernicterus, prevention	4/7 L	Nitrofurantoin, breastmilk	7/7 L
Ketogenic diet	4/4 L	Nizatidine	8/12 L
Ketorolac	3/6 L	Non-prescription medications	1/5 L
Ketorolac, kinetics	5/7 L	Non-steroidal anti-inflammatory drugs (NSAIDs) , renal effects	1/6 L
L		Norfloxacin/Cyclosporine	1/11 L
Lamivudine	8/1 M	O	
Lamotrigine	1/3 L, 1/12 L	Obesity, therapy	3/11 L
	5/3 M	Olanzapine	7/8 M
Lamotrigine, dose relationship	3/8 L	Omeprazole	5/4 M
Lamotrigine, kinetics	5/7 L	Ondansetron	3/9 M
Lansoprazole	5/4 M, 8/7 L	Ondansetron, kinetics	1/11 L
Levalbuterol, assessment	5/3 L	Ondansetron, outpatient use	1/2 L
Levetiracetam	8/7 M	Opioids, respiratory depression	2/3 L
Lice, treatment	1/8 M	Opioids, tolerance and dependence	6/7 M
Lindane	1/8 M	Oral contraceptives	1/3 L
Loracarbef	2/6 M	Oseltamivir	6/12 F, 7/2 M
Loratadine	1/9 M, 7/4 M	Otitis media, therapy	4/10 L, 7/3 L
Lovastatin	8/9 M	Over-the-counter recommendations	4/9 L
Low-molecular-weight heparins	3/6 M	Oxcarbazepine	7/11 M
M		P	
Macrolides	2/2 M, 3/4 L	Pain management	2/3 L, 2/6 L
	5/2 L	Palivizumab	4/9 M, 6/2 L
Macrolides, drug interactions	1/9 L	Parenteral nutrition	1/3 L, 5/12 L,
Magnesium, use in asthma	5/7 L		8/4 L
Malathion	1/8 M	Paroxetine	2/10 M

Paroxetine/Atomoxetine	8/12 L	Serum sickness, cross-sensitivity	4/7 L
Patient-controlled analgesia	6/11 M	Simvastatin	8/9 M
Patient education	3/8 M	Sinusitis, therapy review	6/7 L
Pediatric pharmacology library	1/6 M	Skin reactions, drug-induced	1/9 L, 4/11 M
Pemoline	1/12 M, 8/4 M	Smoking cessation	1/3 L
Pemoline, liver failure	1/8 L, 4/5 L	Sodium bicarbonate	2/12 M
Permethrin	1/8 M	Solvents	2/9 M
PGE ₁	6/9 M	Sotalol	7/3 L, 7/4 L
Pharmacists' OTC recommendations	4/9 L	Spirolactone	1/10 M
Pharmacokinetics, review	8/12 L	Splitting tablets	4/3 L
Phenobarbital, dialysis	3/10 L	Stevens-Johnson syndrome	4/11 M
Phenobarbital, ECMO	5/6 L	Sufentanil	2/5 L, 8/1 M
Phenothiazines, review	5/10 L	Sulfamethoxazole-trimethoprim	4/4 M
Phenytoin	2/8 M, 7/5 L	Supraventricular tachycardia (SVT)	4/6 L
Phenytoin, con. in neonates	4/4 L	Supraventricular tachycardia (SVT), treatment	4/6 L
Phenytoin/Enteral feedings	6/9 L	Surfactants	2/3 L, 4/9 L
Phosphate overdose	3/12 L	Sweeteners	2/9 M
Photosensitivity, drug-induced	4/6 M	T	
Pimecrolimus	8/1M, 8/5 M	Tacrolimus	4/2 L, 4/10 L, 7/3 L
Placebo response	2/11 L	Tacrolimus/Enteral feedings	4/8 L
Placental drug transfer, mechanisms	1/4 L	Tacrolimus, topical	8/5 M
Placental drug transfer, model	2/1 L	Taste, effect on compliance	3/11 L
Pneumococcal vaccine	5/12 M	Terfenadine	1/9 M
Poison prevention	6/8 M, 7/3 M	Terfenadine, breastmilk transfer	1/5 L
Polio vaccine	1/3 M, 2/3 M	Theophylline, dosing	1/4 L, 1/9 L
Polyethylene glycol	4/3 M	Theophylline, drug interactions	1/5 L
Portactant	3/7 M, 7/3 M	Therapeutic drug monitoring	1/7 M
Pravastatin	2/9 M	Therapeutic equivalence	2/12 L
Pregnancy, antiarrhythmics use	5/12 M	Thimerosal	7/3 M
Pregnancy, cefuroxime use	8/9 M	Ticarcillin/clavulanic acid	1/9 L
Pregnancy, hydroxyurea use	5/5 L	Tobramycin, dosing in CF	2/5 L
Pregnancy, labeling changes	6/4 L	Tobramycin, lung transplant	4/6 L
Pregnancy, metabolic function	6/1 L	Tobramycin, neonatal kinetics	3/11 L
Preservatives	6/12 F	Topiramate	4/5 L, 5/12 M, 7/6 M, 7/11 L, 8/1 M
Preservatives, nebulizer solution	3/11 L	Toxic epidermal necrolysis	4/11 M
Propafenone, during CVVH	2/9 M	Triamcinolone	2/1 M, 7/5 M
Propofol	4/3 L	Trimethoprim-sulfamethoxazole	4/4 M
Propylene glycol	5/10 L	U	
Prostaglandin E ₁	6/5 M	Urosdeoxycholic acid, use in CF	3/11 L
Protease inhibitors	6/9 M	V	
Proton pump inhibitors	7/3 L	Vaccines	3/7 M, 7/3 M
Psychiatric disorders, therapy	5/4 M	Vaccines, adverse reactions	1/3 M, 3/7 M
Psychotropic use, predicting	2/6 L	Vaccines, storage	1/6 M
Pyrazinamide	1/12 L	Valacyclovir	8/6 M
Pyrethrins	8/8 L	Valproate, kinetics	1/12 L
Q	1/8 M	Valproic acid	3/3 M, 5/7 L
Quetiapine	7/8 M	Vancomycin	1/2 M, 3/9 L, 5/12 L
Quinine	5/6 L	Vancomycin, monitoring	3/8 L
R		Vancomycin, neonatal kinetics	3/11 L, 7/9 L
Recent advances in pharmacology	1/2 L	Vancomycin-resistant organisms	1/2 M
Renal drug interactions	4/7 L	Varicella vaccine	1/2 F
Respiratory syncytial virus (RSV)	3/10 M, 4/2 L	Vecuronium	5/9 M
Respiratory syncytial virus (RSV) immune globulin	4/9 M, 6/2 L	Vitamin K	1/4 L, 7/10 M
Reye's syndrome	8/8 L	Vitamin supplements	3/4 M
Ribavirin	3/10 M	Volume of distribution	1/7 M
Risperidone	2/5 L, 7/8 M	W	
Rocuronium	6/10 M	Warfarin	1/1 M
Rotavirus vaccine	5/2 M, 6/12 F	Warfarin/Fluconazole	2/5 L
S		Warfarin, kinetics	6/12 L
Saline vs. heparin in catheters	4/4 L	X-Z	
Salmeterol	1/1 F	Zafirlukast	5/12 M
Saquinavir	8/5 L	Zidovudine, drug interactions	4/1 L
Scabies, treatment	1/8 M, 2/8 L	Zidovudine, kinetics in infants	5/9 L
Scientific bias	3/9 L	Zidovudine, use in pregnancy	1/8 L
Sedatives	4/10 L	Zinc, use in common cold	4/2 L
Sedatives, kinetics in neonates	3/3 L	Ziprasidone	7/8 M
Selective 5HT ₃ reuptake inhibitors	2/10 M		
Sertraline	2/10 M		
Sertraline/Erythromycin	5/9 L		

Contributing Editor: Marcia L. Buck, Pharm.D.

Editorial Board: Anne E. Hendrick, Pharm.D.

Michelle W. McCarthy, Pharm.D.

Kristi N. Hofer, Pharm.

If you have any comments or suggestions for future issues, please contact us at Box 800674, UVA Medical Center, Charlottesville, VA 22908, by phone (434) 982-0921, or by e-mail to mlb3u@virginia.edu.